Valneva SE Commences Private Placement to Raise 60 Million Euros

Saint-Herblain (France), September 12, 2024 - Valneva SE VALN, a leading specialty vaccine company, has announced the initiation of a significant private placement. The ambitious move seeks to raise approximately 60 million euros through the issuance of approximately 22.6 million new ordinary shares, known as the 'Offer Shares'. This strategic financial action is predicated on prevailing market conditions.

Investment Drive for Therapeutic Advancements

Headquartered in the vibrant community of Saint-Herblain, France, Valneva SE is at the forefront of creating vaccines to address infectious diseases that presently lack effective preventive solutions. By undertaking this private placement, the company aims to generate capital to further its research and development efforts, enhancing its ability to deliver life-saving vaccines to the market.

Terms and Impact of the Private Placement

The process of the private placement involves the creation of new ordinary shares which will be offered to select institutional investors. The exact terms, including pricing and the final number of Offer Shares, will be determined by the company in accordance with market feedback and conditions. This financial maneuver is designed to strengthen Valneva SE's balance sheet and support its ongoing and future projects, thereby potentially improving its position within the pharmaceutical industry and generating long-term value for its shareholders.

The ticker symbol for Valneva SE, VALN, may witness fluctuations as investors and the stock market respond to the news of the private placement. Interested parties are encouraged to follow these developments closely to understand the possible impact on their investment decisions.

PrivatePlacement, Vaccines, Healthcare